Almac
NCCN Calls ctDNA Emerging Colon Cancer Prognostic Marker, Does Not Back Use Outside Clinical Trials
The panel noted limited data on whether recurrence risk scores from ctDNA testing or multigene assays predict chemotherapy benefit among colon cancer patients.
The new tests, once developed, will be used for selecting patients who might best benefit from therapies for kidney disease, nonalcoholic steatohepatitis, and respiratory disease.
Almac NGS-Based CDx Gets CE Mark
Almac said that the assay will be used in a clinical study of repotrectinib (TPX-0005), an investigational, next-generation tyrosine kinase inhibitor.
The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.
FDA Grants IDE Approval for Almac Diagnostic Services' CDx for Use in Cancer Drug Study
The next-generation sequencing assay is intended for use in identifying patients with ROS1, NTRK1-3, and ALK gene fusions in advanced solid tumors.